NCT04599426Unknown1 期
Safety and Efficacy of Allogenic NK Cell Transfusion Combined With Azacitidine Therapy for the MDS-EB
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR) (PR+CR)
研究概览
简要总结
The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for refractory MDS-EB.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with refractory high-risk MDS (MDS-EB1 and EB2) who had no effect of 2 courses of desitabine or CAG or desitabine + CAG.
- •Patients with age 15 years to 70 years.
- •KPS greater than or equal to
- •ALT and AST are less than 3 times normal.
- •Total bilirubin less than 1.5mg/dl(25.65umol/L).
- •Serum creatinine less than 2.5mg/dl(221umol/L), or creatinine scavenging ability greater than or equal to 60 mL/min/1.73 m
- •Left ventricular ejection fraction cardiac greater than or equal to 45%, Echocardiography (ECHO) showed no pericardial effusion, Electrocardiogram (ECG) is normal.
- •No pleural effusion in lungs.
- •Oxyhemoglobin saturation greater than or equal to 92% in normal environment.
- •Women of child-bearing age have negative urine pregnancy tests before administration began, and agree to use effective contraception during the trial period up to the last follow-up.
- •KIR mismatch between patient and umbilical cord blood.
- •Volunteer to participate in the trial and sign the informed consent form.
排除标准
- •Malignant tumor patient.
- •Patients who are accompanied by fungal, bacterial, viral, or other uncontrolled infections or require level 4 isolation. (HBV-DNA quantification and normal liver function in patients with hepatitis b infection are excluded).
- •Patients with HIV, HCV positive.
- •Patients with central nervous system diseases, including stroke, epilepsy, dementia, or autoimmune central nervous system disorders.
- •Patients with central nervous system diseases, including stroke, epilepsy, dementia, or autoimmune central nervous system disorders.
- •Patients receiving anticoagulant therapy or with severe coagulation disorders.
- •According to the researcher's judgment, the drug treatment the patient is receiving will affect the safety and effectiveness of the study.
- •Patients with allergies or history of allergies to biological agents used in this program.
- •Lactating or pregnant women.
- •Systemic steroid used within 2 weeks before treatment (except for recent or present use of inhaled corticosteroids).
- •Patients with other uncontrolled diseases, Investigators think it is not suitable for the participants.
- •Any circumstance that the investigator considers may increase the risk to the subject or interfere with the results of the study.
- •Patients participate in other clinical studies.
结局指标
主要结局
Objective Response Rate (ORR) (PR+CR)
时间窗: 3 months
The proportion of patients with complete response(CR) or partial response(PR) as measured by International Working Group efficacy Criteria for myelodysplastic syndromes
次要结局
- Overall survival(OS)(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
NK Cell Therapy Recurrent/Refractory Elderly AMLRecurrentRefractoryElderlyAMLNCT04599452The Second Hospital of Shandong University10
Unknown
1 期
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT04162158Beijing 302 Hospital200
尚未招募
早期 1 期
Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological MalignanciesHematological MalignanciesNCT04662788Zhejiang University36
Unknown
2 期
A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung CancerNon-small Cell Lung CancerNCT02734524Southwest Hospital, China104
Unknown
1 期
NK Cells Infusion for Advanced MalignanciesImmunotherapyNCT03619954Anhui Provincial Hospital50